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ABSTRACT 18 
The kinetochore is a macromolecular structure that assembles on the centromeres of 19 
chromosomes and provides the major attachment point for spindle microtubules during 20 
mitosis. In Trypanosoma brucei the proteins that make up the kinetochore are highly 21 
divergent, with the inner kinetochore comprising at least 20 distinct and essential 22 
 
 
proteins (KKT1-20) that include four protein kinases, CLK1 (KKT10), CLK2 (KKT19), 23 
KKT2 and KKT3. We report the identification and characterisation of the 24 
amidobenzimidazoles (AB) protein kinase inhibitors that have nanomolar potency 25 
against T. brucei bloodstream forms, Leishmania and Trypanosoma cruzi. Target 26 
deconvolution using a selection of 31 T. brucei mutants that over-express known 27 
essential protein kinases identified CLK1 as a primary target. Biochemical studies and 28 
the co-crystal structure of CLK1 in complex with AB1 show that the irreversible 29 
competitive inhibition of CLK1 is dependent on a Michael acceptor forming an 30 
irreversible bond with C215 in the ATP binding pocket, a residue that is not present in 31 
human CLK1, thereby providing selectivity. Chemical inhibition of CLK1 impairs 32 
inner kinetochore recruitment and compromises cell cycle progression, leading to cell 33 
death. This work highlights a unique drug target for trypanosomatid parasitic protozoa 34 
and a new chemical tool for investigating the function of their divergent kinetochores.  35 
 36 
Main Text 37 
The three kinetoplastid neglected tropical diseases; leishmaniasis, Chagas disease, and human 38 
African trypanosomiasis (HAT) remain a significant global health burden. Over a billion 39 
people living in endemic regions are at risk from these neglected diseases with an estimated 40 
30,000 deaths annually (WHO)1. While there have been notable recent advances in disease 41 
control, current therapies have severe shortcomings and there is an urgent need for innovative 42 
treatments that are safe, efficacious and easy to administer. Some of the significant advances 43 
include the development of novel oral therapy for sleeping sickness2,3 and identification of 44 
pre-clinical candidates for leishmaniasis4–6. In order to find additional growth inhibitors, a 45 
whole parasite based phenotypic screen was carried out using ~2.3 million compounds 46 
against bloodstream forms of T. brucei4, which included the Novartis kinase focused inhibitor 47 
library. This led to the identification of AB0, an Amidobenzimidazole (Fig. 1a and 48 
Supplementary Figure 1a) with an EC50 of 290 nM in an in vitro T. brucei parasite growth 49 
inhibition assay (Fig. 1a).  50 
Detailed structure activity relationship (SAR) studies using ~250 close analogs obtained from 51 
the Novartis compound archive and focused medicinal chemistry efforts were carried out. 52 
The growth inhibition activity of compounds against T. brucei ranged 3 log orders with many 53 
compounds showing < 100 nM potency. Results also showed that the analogs having Michael 54 
 
 
acceptor chemical functionality are critical for potent activity and afford higher lipophilic 55 
efficiency (LipE >3) required for more favourable drug-like properties (Fig. 1b, 56 
Supplementary Table 1). SAR analysis also led to the identification of more potent bioactive 57 
compounds, including AB1 (EC50 of 72 nM against T. brucei), with a >100-fold cytotoxicity 58 
window (Fig. 1a). AB1 not only showed potent activity against T. b. gambiense and T. b. 59 
rhodesiense, the causative agents of sleeping sickness but also had pan-kinetoplastid activity 60 
against T. cruzi (aetiology for Chagas disease), Leishmania mexicana (cutaneous 61 
leishmaniasis) and L. donovani (visceral leishmaniasis) suggesting that the molecular target is 62 
conserved across trypanosomatids (Fig. 1a). Compound AB1 was cidal to T. brucei showing 63 
concentration and time dependent kill, further it also exhibited relapse free cidality in wash-64 
off assays suggesting ability to achieve sterile cure (Extended data 1b, c). In vitro wash-off 65 
assays are presumed to be predictive of compounds’ ability to achieve relapse free cure in the 66 
mouse model of infection. AB1 had better solubility and in vitro pharmacokinetic properties 67 
with moderate to low clearance in mice, rat and human microsomes (Fig. 1a), allowing us to 68 
evaluate the ability to cure T. brucei infection in mouse models.  69 
In vivo efficacy of AB1 was tested in mice with haemolymphatic and central nervous system 70 
(CNS) T. brucei infections using both STIB795 and GVR35 optimised bioluminescence HAT 71 
mouse models7. A dose dependent cure was observed with AB1, resulting in relapse free cure 72 
with a daily oral dosage of 50 mg/kg for four consecutive days in the STIB795 73 
haemolymphatic mouse model of infection (Fig. 1c). However, despite a 4 log reduction in 74 
parasitaemia observed in a pleomorphic GVR35 strain chronic (CNS) model of infection, the 75 
parasitemia relapsed, most likely due to poor access of AB1 to parasites in the brain 76 
(Extended data 2a,b). Although AB1 showed good brain partitioning (measured brain to 77 
plasma ratio was 0.5), due to high brain tissue binding (>99%), the free fraction available for 78 
acting against the parasites in the brain was negligible, leading to poor efficacy (Extended 79 
data 2c,d). Further medicinal chemistry optimization is required to find compounds with 80 
better pharmacokinetic properties in order to achieve cure in the CNS model. The mouse 81 
efficacy studies using AB1 showed in vivo chemical validation of AB series compounds as 82 
promising anti-trypanosomatid candidates. 83 
AB1 is a known covalent inhibitor of mutant human epidermal growth factor receptor 84 
(hEGFR) kinase, a well-studied target for non-small cell lung cancer (Fig 1a)8. Whilst 85 
hEGFR belongs to the tyrosine kinase family, the T. brucei genome lacks members of the 86 
receptor-linked or cytosolic tyrosine kinase families9. A major challenge for phenotypic hits 87 
 
 
is to identify the molecular target that is responsible for that effect. Since AB series 88 
compounds were hypothesized to target protein kinases, we generated inducible T. brucei 89 
gain-of function mutants of individual protein kinases to screen for resistance to AB1 (Fig. 90 
2a). Twenty-nine essential protein kinases that had been assessed previously by RNAi as 91 
having specific RNAi induced cell cycle defects in bloodstream forms (BSF)10 were 92 
analysed. In our screen, only one protein kinase, CLK1, showed a significant 6.5-fold 93 
increase in resistance compared with its uninduced control (Fig. 2b). In general over-94 
expression of protein kinases show moderate resistance to their inhibitors. Wyllie and co-95 
workers showed that co-over expression of CYC9 and wild type CRK12 in L. donovani 96 
resulted in 3-fold shift in cellular EC50 against the compound 5 (DDD853651/GSK3186899), 97 
validating CRK12 as the target5. Over-expression of PI4K (phosphatidylinositol 4-kinase) in 98 
Plasmodium falciparum also rendered moderate 3-fold shift in EC50 against imidazopyrazine 99 
compounds, confirming the on-target effect11.  100 
In mammals, CLK1 belongs to the Clk (Cdc2-like kinase) family implicated in RNA splicing 101 
control and consists of at least four members12. In T. brucei, CLK1 is a kinetochore 102 
component essential for mitosis and has been proposed to be one of the potential targets for 103 
the fungal antibiotic hypothemycin13–15. As treatment with AB1 resulted in a G2/M cell cycle 104 
arrest (Fig. 2c-e) with most of the treated cells having an enlarged nucleus (Fig. 2d) similar to 105 
CLK1 RNAi knockdown (Extended data 3a-c), we tested if overexpression of CLK1 would 106 
confer resistance to drug-induced G2/M cell cycle arrest. Indeed, parasites overexpressing 107 
CLK1 had a normal cell cycle profile after treatment with AB1, in comparison to the parental 108 
cell line and DMSO uninduced control, which were G2/M arrested after treatment (Fig. 2c). 109 
CLK1 overexpression impairs parasite fitness without affecting cell cycle progression, 110 
suggesting that T. brucei tightly regulates CLK1 expression (Extended data 3d). In addition, 111 
AB1 attenuates CLK1 toxicity caused by over-expression, providing further evidence that 112 
CLK1 is the compound’s primary target (Extended data 3e, f).  113 
We expressed recombinant TbCLK1 and human CLK1 and tested ~230 compounds from the 114 
AB series to determine the biochemical SAR. Apparent IC50 was determined after 10 min 115 
post-incubation with the enzyme. A strong correlation was observed between inhibition of the 116 
T. brucei CLK1 enzyme and cellular activity (Pearson’ correlation r = 0.68), supporting the 117 
chemical validation of CLK1 as the molecular target for the amidobenzimidazole series of 118 
compounds (Fig. 3a, Supplementary Table 1). The majority of the compounds showed greater 119 
selectivity against TbCLK1 compared to hCLK1 (Fig. 3b, Supplementary Table 1). AB1 120 
 
 
inhibited TbCLK1 with an apparent IC50 of 10 nM, with 90-fold selectivity observed over 121 
hCLK1 (Fig. 3b). T. brucei also has another protein kinase, CLK2, which is closely related to 122 
CLK1, with 92% overall sequence identity and 100% identity in the protein kinase domain. 123 
CLK2 is less abundant than CLK1 in bloodstream forms (Extended data 4a, b). AB1 would 124 
be expected to inhibit the kinase activity of CLK2, but this is unlikely to contribute to killing 125 
in bloodstream forms of the parasite as CLK2-specific RNAi suggests the protein is not 126 
essential13. 127 
Interestingly, all compounds with a Michael acceptor inhibited TbCLK1 kinase activity but 128 
not others, strongly suggesting this functionality is an essential feature of the pharmacophore 129 
(Fig. 3a). In order to test the putative critical role played by the Michael acceptor, a 130 
compound similar to AB1, which has a saturated double bond at the Michael acceptor, was 131 
profiled in both enzymatic and cellular assays. This compound (AB2) was completely 132 
inactive in both TbCLK1 enzyme (apparent IC50 > 20 µM) and whole cell growth inhibition 133 
assays (Tbb EC50 > 50 µm), confirming the importance of the Michael acceptor for activity 134 
(Supplementary Table 1). The hEGFR inhibitors having Michael acceptors are known to 135 
covalently interact with an active site cysteine (C797) near the ATP binding domain8,16.  136 
In order to directly visualize the binding mode, structure of TbCLK1 kinase domain bound to 137 
AB1 was determined to 2.7Å (PDB 6Q2A) (Fig. 3c). At this resolution, the electron density 138 
map has continuous density between the side-chain of the thiol group of C215 and the 139 
Michael acceptor of the inhibitor (Fig. 3c, d), strongly indicating the formation of an 140 
irreversible covalent bond between them. Furthermore, AB1 forms direct hydrogen bonds 141 
with the backbone amide NH of Y212 and C215 and a salt bridge with D218 (Fig. 3c), 142 
consistent with the binding mode of AB1 when covalently attached to hEGFR8. While both 143 
hEGFR and TbCLK1 have cysteine in their active sites, hCLK1 lacks cysteine and instead 144 
has serine in the same position (Extended data 5a-c). This has led to achieving significant 145 
selectivity for most AB series compounds for TbCLK1 (Fig. 3b). Beyond the AB1 binding 146 
site, the TbCLK1 kinase domain exhibits an overall structure that is in line with a kinase in 147 
the active conformation, closed kinase lobes, a well-ordered activation loop, DLG-in and an 148 
intact salt bridge to αC-helix (Fig. 3c).  149 
To investigate the covalent binding and interaction with C215, we co-incubated AB1 and 150 
AB2 with both wild type and C215A mutant of TbCLK1 and assessed the interaction using 151 
biophysical methods. As expected, incubation of AB1 with wild type TbCLK1 enzyme 152 
 
 
resulted in a 12° C shift in denaturing temperature as seen by differential scanning 153 
fluorimetry (Fig. 4a and Extended data 6a). Similarly, mass spectrometric analysis also 154 
showed one main product per protein which has an average mass 475 Da higher than the 155 
unmodified protein (Extended data 6b). This was consistent with the addition of one molecule 156 
of AB1, which has a mass of 475 Da. No shift in the mass was seen for AB2, or in C215A 157 
mutant CLK1 (Extended data 6a). These results clearly show covalent interaction of the 158 
Michael acceptor with C215 of TbCLK1. In addition, TbCLK1 C215A is not inhibited by 159 
AB1, but is inhibited by the non-covalent pan-kinase inhibitor staurosporine (Fig. 4b). 160 
Multiple sequence alignment of CLK1 from T. brucei, T. cruzi and L. mexicana showed high 161 
sequence similarity and C215 was conserved across parasites, further suggesting the growth 162 
inhibition of these parasites by AB1 could be due to TbCLK1 inhibition (Extended data 4c).  163 
Further, to assess the importance of T. brucei CLK1 C215 in AB1 binding in parasites, a 164 
recoded version of CLK1 that contained a Cys to Ala mutation at position 215 was expressed 165 
in the TbCLK1 RNAi line. In this cell line, RNAi induction depleted the wild type CLK1 166 
mRNA but the recoded CLK1 C215A mRNA was not susceptible to RNAi-induced 167 
degradation and was expressed. This triggered a G2/M cell cycle arrest, suggesting this 168 
residue is important for CLK1 function and may mimic AB1 –TbCLK1 mediated inhibition. 169 
Since expression of the C215A mutation affected the fitness of the parasites, we attempted to 170 
express a C215S mutation, as human CLK1 has serine at position 215. Parasites expressing 171 
the TbCLK1 C215S mutation had a normal cell cycle profile (Extended data 7a, b) and were 172 
resistant to treatment with 5x EC50 of AB1 (Extended data 7c). Thus, we evaluated if the 173 
overexpression of the C215S mutation in the parental cell line increased this resistance, and 174 
indeed, this mutation conferred a > 60-fold EC50 shift of resistance against AB1 (Fig. 4c), 175 
which also significantly reduced the effect of AB1 in the parasite’s growth and survival (Fig. 176 
4d, e). Interestingly, we observed that AB1 treatment induced a mobility shift on CLK1, 177 
which likely corresponds to phosphorylation, whilst the C215S mutant protein remained 178 
unaltered (Extended data 7d). Together, these data demonstrate target engagement in the 179 
parasite and inhibition of CLK1 with AB1.  180 
TbCLK1 (KKT10) is a core component of the inner kinetochore. In other organisms, the 181 
kinetochore supports directional movement of chromosomes into microtubules to ensure 182 
faithful chromosome segregation17. Some of the T. brucei kinetochore components have been 183 
recently described, and grouped according to their patterns of expression/localization through 184 
the cell cycle14,18. The significant divergence between components of the human and parasite 185 
 
 
kinetochores underpins its potential druggability. Although depletion of TbCLK1 has been 186 
associated with the presence of lagging chromosomes during mitosis in procyclic cells14 the 187 
causal link of TbCLK1 to this process has yet to be established. To investigate this further T. 188 
brucei bloodstream form cells were synchronised by cell sorting19 to give 2C and 4C nuclear 189 
DNA content populations and then allowed to enter the cell cycle in the presence or absence 190 
of AB1 (Fig 2e and Extended data 8 a-c). Inhibition of TbCLK1 in the 2C population (G1-191 
phase) synchronously progressing through the cell cycle led to arrest of cells in late 192 
metaphase with a 2K1N configuration (defined as cells having 2 kinetoplasts (2K) and 1 193 
nucleus (1N)). By contrast, inhibition of TbCLK1 in the 4C population synchronously 194 
progressing through the cell cycle induced an arrest in the late anaphase (2K2N population). 195 
These data are consistent with inhibition of TbCLK1 causing a disruption in kinetochore 196 
function during metaphase and exit from anaphase into cytokinesis. To confirm this, we 197 
tagged KKT2, a canonical centromere kinetochore protein, with mNeonGreen and assessed 198 
its localisation in the presence and absence of AB1. Similar to previous observations in 199 
procyclic form cells14,18, we observed in bloodstream form cells that KKT2 is constitutively 200 
expressed until anaphase. Treatment with either 2 x EC50 of AB1 for 24 hr or 5 x EC50 of 201 
AB1 for 6 hr caused dispersal of the defined foci of the kinetochore within the nucleus (Fig. 202 
5a). This change of KKT2 pattern was also observed after depletion of CLK1 by RNAi (Fig. 203 
5b). These data demonstrate that inhibition of CLK1 by AB1 causes impairment of 204 
kinetochore function thereby defining a consequence of AB1 treatment.  205 
Discussion 206 
Our studies indicate that the principal mechanism of action for the amidobenzimidazole series 207 
is inhibition of the trypanosome CLK1 protein kinase.  In support of this, we show for over 208 
230 compounds that a strong correlation exists between inhibition of recombinant TbCLK1 209 
and killing of the parasite.  Only those compounds that have a Michael acceptor and are 210 
predicted to form a covalent bond with C215 of CLK1 are active and the X-ray structure, 211 
differential scanning fluorimetry and mass spectrum chromatograms clearly demonstrate the 212 
covalent linkage for AB1.  We also show that over-expression of CLK1 or the CLK1 C215S 213 
mutant provide 6.5-fold or >60-fold resistance of the parasite to AB1, respectively, 214 
demonstrating target engagement. AB1 treatment of bloodstream form trypanosomes lead to 215 
chromosome mis-segregation and cell cycle arrest, consistent with inhibition of CLK1, which 216 
is a kinetochore kinase (KKT10).  Generation of parasites resistant to compounds and the 217 
identification of mutations in target genes is a well-established method for target 218 
 
 
deconvolution4,5.  However, we failed to generate parasites resistant to AB1, even after a year 219 
and half under compound selection.  This might be explained if AB1 has an element of 220 
polypharmacology and one potential secondary target is CLK2, which is an active enzyme20 221 
and has an identical protein kinase domain to CLK1, thus inhibited by AB1.  In procyclic 222 
form trypanosomes CLK1 and CLK2 are functionally redundant21, whilst in bloodstream 223 
form parasites CLK1 is essential, but CLK2 is not essential15,22.  An explanation for this 224 
arises from our finding that CLK1 is more highly expressed than CLK2 in bloodstream 225 
forms, such that inhibition of CLK1 activity leads to chromosome mis-segregation and cell 226 
cycle arrest, phenotypes consistent with inhibition of a kinetochore kinase (KKT10).  227 
 228 
We propose that inhibition of CLK1 activity with AB1 leads to impaired kinetochore 229 
function and irreversible arrest in metaphase leading to cell death. A combination of growth 230 
inhibition screening, target identification and characterization resulted in the chemical 231 
validation of CLK1 as a unique pan-kinetoplastid drug target. In recent years six covalent 232 
inhibitors of protein kinases have been successfully approved for cancer treatment23, 233 
underlining the possibility of developing covalent inhibitors into drugs.  The combination of a 234 
distinct mechanism of action targeting the kinetochore, and a new series of 235 
antitrypanosomatid AB compounds, which have reduced chances of acquiring resistance in 236 
the clinic, add to the proteasome and CRK12 inhibitors already entering clinical trials4,5,24,25.  237 
One of the key challenges for the AB series of compounds to progress to the clinic is to 238 
improve kinase selectivity and the co-crystal structure determined in the current study will 239 
significantly help in structure based medicinal chemistry optimization to resolve this issue. 240 
The current efforts of CLK1 target validation also open up opportunities for focused 241 
structure-based drug design using fragment screens in order to obtain non-covalent inhibitors 242 
that have pan-kinetoplastid growth inhibition properties. In addition, the high level of 243 
sequence divergence of trypanosome kinetochore complex proteins from humans 14,26 make 244 
the kinetochore a high value target. 245 
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METHODS 271 
 272 
Cellular assays 273 
 274 
A kinase focused inhibitor library (containing approximately 10,000 compounds) was 275 
screened at a single concentration of 10 µM for the ability of compounds to inhibit growth of 276 
T. b. brucei Lister 427. This resulted in 2264 compounds showing > 50% growth inhibition. 277 
Chemi-informatic analysis of hits resulted in ~200 clusters, representatives of these were 278 
subjected to 10-point dose-response growth inhibition assays against bloodstream form of T. 279 
b. brucei Lister 427. Further removal of non-favourable chemical structures such as 280 
 
 
nitrofuranes, cytotoxicity profiling using the HepG2 cell line (selectivity index of 10) and 281 
favourable physico-chemical properties (polar surface area <100; molecular weight <500 and 282 
lipophilicity <4.5) led to identification of an amidobenzimidazole scaffold (AB0) for further 283 
follow up.  284 
 285 
Bloodstream form of Trypanosoma brucei brucei Lister 427, T. b. gambiense STIB930 and 286 
T. b. rhodesiense STIB900 were cultured in HMI-9 medium as described elsewhere4. 287 
Other kinetoplastid parasites Leishmania donovani HU3 and L. mexicana 288 
(MNYC/BZ/62/M379) were cultured in RPMI 1640 media as described earlier 4,27. The T. 289 
cruzi Tulahuen parasites constitutively expressing Escherichia coli β-galactosidase28 were 290 
maintained in tissue culture as an infection in NIH 3T3 fibroblast cells4. NIH 3T3 and 291 
human epithelial (HepG2) cells were obtained from ATCC and grown in RPMI media 292 
(Life Technologies).  293 
All other transgenic T. b. brucei parasites used in this study were derived from 294 
monomorphic T. b. brucei 2T1 bloodstream forms29 and were cultured in HMI-11 [HMI-9 295 
(GIBCO) containing 10% v/v foetal bovine serum (GIBCO), Pen/Strep solution (penicillin 296 
20 U ml−1, streptomycin 20 mg ml−1)] at 37 °C/5% CO2 in vented flasks. Selective 297 
antibiotics were used as follows: 5 μg ml−1 blasticidin or hygromycin and 2.5 μg 298 
ml−1 phleomycin or G418. RNAi or overexpression was induced in vitro with tetracycline 299 
(Sigma Aldrich) in 70% ethanol at 1 μg ml−1. Endogenous Ty, mNeonGreen or myc-300 
overexpression tagging were performed using the pPOTv6 vector30  and pRPa29, respectively. 301 
The generation of inducible TbCLK1 RNAi was generated as previously described 13. All 302 
primers are listed in Supplementary methods Table 1. 303 
 304 
All cell based assays were performed as described before 4,31. Briefly, bloodstream form of T. 305 
b. brucei Lister 427, T. b. rhodesiense and T. b. gambiense parasites were incubated with 306 
varying concentration of compounds for 48 hr. Cell viability was assessed by measuring ATP 307 
levels using  CellTiter-Glo reagent (Promega) and 50% growth inhibition (EC50) was 308 
calculated using sigmoidal dose response curves. For both intracellular T. cruzi amastigotes 309 
and L. donovani HU3 axenic amastigotes growth inhibition was measured as described 310 
earlier4. Intracellular L. mexicana amastigote growth inhibition was assessed by microscopy. 311 
Briefly, after primary peritoneal mouse macrophages were infected with late-log-phase 312 
promastigotes at an infection ratio of 10:1; non-internalized parasites were removed by 313 
 
 
washing the plates with PBS, and cells were cultured with different drug concentrations for 314 
96 hr. Determination of intracellular parasite numbers were done by fixing the cells in 315 
methanol and then stained with DAPI .Cytotoxicity (CC50) was also measured against mouse 316 
fibroblast NIH 3T3 and HepG2 cell lines by incubating compounds for 4 days4. 317 
Single protein kinase overexpression lines (Supplementary methods table 1) were generated 318 
by transfecting T. brucei brucei 2T1 cells with a tetracycline inducible overexpression 319 
plasmid linearized with AscI restriction enzyme. Each overexpression construct contains the 320 
open reading frame (ORF) of a single protein kinase in the plasmid pGL2220 (pRPa-321 
iMYCx)32. This plasmid integrates at the tagged rRNA spacer (single locus) of 2T1 T. brucei.  322 
Protein kinase overexpression cell lines were adjusted to 2 × 105 cells ml−1 and induced for 323 
18 hr by the addition of tetracycline to a final concentration of 1 µg ml−1 in 70% ethanol. To 324 
establish the EC50, the protein kinase overexpression cell lines and parental control 2T1 were 325 
treated with two-fold increasing concentrations of compounds (with similar DMSO 326 
increasing concentration as control). Cell viability was measured at 48 hr with a POLARstar 327 
Omega plate reader spectrophotometer; the determination of cell viability was carried out by 328 
the established colorimetric technique using Alamar Blue (0.49 mM resazurin in phosphate-329 
buffered saline (PBS)), in a 96-well plate format spectrophotometric assay which measures 330 
the ability of living cells to reduce resazurin. We used pentadimine isethionate (Sigma 331 
Aldrich) as a positive control. Fluorescence emission was detected using a CLARIOstar ® 332 
reader (BMG LABTECH; excitation filter at 540 nm and emissions filter at 590 nm). Fitting 333 
of dose-response curves and IC50/EC50 determination were normalized as percentage of 334 
inhibition based on controls. Hesperadin was obtained from ApexBio Technology.  335 
 336 
Mouse infection models for T. brucei. 337 
The T. brucei strain STIB795 acute mouse model mimics the first stage of African 338 
trypanosomiasis33. Six female NMRI mice were used per experimental group, divided into 339 
two cages (A and B). Each mouse was inoculated by intraperitoneal injection with 104 340 
bloodstream forms of STIB795, respectively. Heparinized blood from a donor mouse with 341 
approximately 5 x 106 ml−1 parasitaemia was suspended in phosphate saline glucose (PSG) to 342 
obtain a trypanosome suspension of 1 × 105 ml−1. Each mouse was injected with 0.25 ml. 343 
Compounds were formulated in 0.5% Tween80 in 0.5% methylcellulose. Compound 344 
treatment was initiated 3 days post-infection and administered orally on four consecutive 345 
 
 
days in a volume of 0.1 ml/10 g. Three mice served as infected-untreated controls. They were 346 
not injected with the vehicle alone since we have established in our labs that these vehicles do 347 
not affect parasitaemia nor the mice. Blood samples were taken after the 4th treatment. From 348 
the mice in cage A, -1 h, 2 h and 8 h after the 4th treatment, 20 uL of blood each were taken 349 
from the tail vein and from mice in cage B 1 h, 4 h, and 24 h after the 4th treatment. 350 
Parasitaemia was monitored microscopically by tail blood examination twice a week until 31 351 
days post-infection. Mice were considered cured when there was no parasitaemia relapse 352 
detected in the tail blood over the 30-day observation period. In vivo efficacy studies in mice 353 
were conducted at the Swiss Tropical and Public Health Institute (Basel) (License number 354 
2813) according to the rules and regulations for the protection of animal rights 355 
("Tierschutzverordnung") of the Swiss "Bundesamt für Veterinärwesen". They were 356 
approved by the veterinary office of Canton Basel-Stadt, Switzerland. 357 
 358 
Plasmids 359 
Recoded CLK1 was synthesised by Eurofins Genomics. The recoded CLK1 sequence 360 
(CLK1R) codes for the same amino acid sequence as CLK1 but only shares 95.06% nucleotide 361 
identity. All segments of identity between CLK1 and CLK1R are less than 20 base pairs 362 
long. CLK1R was inserted by Gibson assembly® (New England Biolabs) into the plasmid 363 
pGL2492 using XbaI and BamHI restriction sites, generating pGL2832. This plasmid is 364 
designed to constitutively express CLK1 from the tubulin locus, with the addition of a C-365 
terminal 6x HA tag. To express the cysteine 215 mutants, the cysteine 215 was changed to 366 
serine or alanine by mutating pGL2832, carrying the coding sequence for CLK1, using site 367 
directed mutagenic PCR (Primer sequences in Supplementary methods).  Similarly, C215S 368 
mutation was introduced into original CLK1 OE plasmid, to generate CLK1 C215S OE 369 
(NITD001 plasmid) into the parental 2T1 cell line. 370 
 371 
Immunofluorescence, cell cycle analysis and cell sorting 372 
Cells treated for 6 hr with compounds or DMSO were centrifuged at 1400 g for 10 min 373 
before washing twice with TDB-glucose at room temperature. Suspensions were centrifuged 374 
at 1000 g for 5 min and pipetted into 6-well microscope slides and dried at RT. Cells were 375 
fixed with 25µl 2% paraformaldehyde diluted in PBS and incubated at room temperature for 376 
5 min. Cells were washed in PBS to remove paraformaldehyde prior to washing twice more 377 
with PBS and permeabilized with 0.05% NP40 for 10 min. Cells were washed twice in PBS 378 
 
 
and dried at RT. Mounting media with DAPI was added to each well with a coverslip. Slides 379 
were kept at 4 oC before viewing using a Zeiss LSM 880 with Airyscan on an Axio 380 
Observer.Z1 invert confocal microscope. 381 
For cell cycle analysis, bloodstream form T. brucei cell lines were incubated or not for 6 hr 382 
with AB compounds at a final concentration of 2X and 5X the individual EC50 value for each 383 
compound (averaged from viability assays). Control cultures were treated with 0.5µl DMSO 384 
but no AB compound. Cultures were pelleted and cells were collected and washed once in 385 
Trypanosoma dilution buffer (TDB) supplemented with 5 mM of EDTA and resuspended in 386 
70% methanol. Cells were centrifuged at 1400 g for 10 min to remove methanol and washed 387 
once in TDB 1x with 5mM EDTA. Cells were resuspended in 1ml TDB 1x with 5mM 388 
EDTA, 10µg ml-1 of propidium iodide and 10µl of RNase A. Cell suspensions in 1.5 ml tubes 389 
were wrapped in foil to avoid bleaching by light. Cells were incubated for 30 min at 37°C in 390 
the dark until FACS analysis. Cells were analysed for FACS using a Beckman Coulter CyAn 391 
ADP flow cytometer (excitation; 535, emission; 617).  392 
 393 
In the cell cycle analysis, CLK1 OE was induced during 18 hr with tetracycline (1 μg ml−1) 394 
and later treated with 4X the individual EC50 value for each compound for 4 hr (maintaining 395 
tetracycline induction), and finally collected for flow cytometry as above.  396 
 397 
Parasite cell sorting was conducted as described previously 19. Briefly, cell lines were 398 
harvested during exponential growth by centrifugation for 10 min at room temperature. The 399 
parasite pellet was then resuspended at a concentration of 1 × 106 cells ml−1 in HMI-9 400 
medium supplemented with 2% FCS and 10 μg ml−1 penicillin/streptomycin. Vybrant 401 
DyeCycle Violet (Molecular Probes, Invitrogen) was added to a final concentration of 1 μg 402 
ml−1and the cell suspension incubated for 30 min at 37 °C, the tube being protected from light 403 
by wrapping in aluminium foil. The samples were then centrifuged and resuspended back in 404 
the staining media prior to sorting on a MoFlo XDP Sorter (Beckman Coulter Life Sciences). 405 
During and after the sorting, the samples were cooled to below 20 °C to limit cell metabolic 406 
activity. The dye was excited using a 407 nm Violet laser and emission detected via a 450/40 407 
bandpass filter. Live parasites were gated based on FSC/SSC profiles, and the gates were set 408 
up to collect only the 2C fraction (G0/G1 cells) and 4C fraction (G2, mitotic and post-mitotic 409 




Protein analysis 412 
Biochemical assays for human EGFR (Epidermal growth factor receptor) and BTK (Bruton’s 413 
tyrosine kinase) were carried out using a homogenous time-resolved fluorescence (HTRF) 414 
assay as described previously 8 . 415 
For enzyme purification, full-length TbCLK1 (Q382U0) CDS was cloned in pET28a PreSc-416 
His and pET24-MBP-TEV vector respectively. Human CLK1 (hCLK1; P49759) was 417 
obtained from Promega. Recombinant expression was carried out by lactose autoinduction in 418 
Terrific Broth containing 0.4% glycerol, 0.05% glucose, 0.05% lactose, 0.05% arabinose and 419 
buffered by 100 mM sodium phosphate (pH 7.0). In brief, 0.7 L of this media (in a 2.8 L 420 
Fernbach flask) was inoculated at 0.1 OD600 with an overnight Luria Broth culture and 421 
shaken at 37 ˚C and 250 rpm for 2.5 hr. Then, temperature was lowered to 18 ˚C and the 422 
culture was allowed to grow and induced overnight and harvested 20-24 hr later. Cells were 423 
pelleted and stored at -80 ˚C prior to purification. Cell lysis was done by sonication in an ice 424 
bath (20 sec ON/OFF, 3 min active sonication at 70-110 watts power) in 40 mL equilibration 425 
buffer (25 mM HEPES pH 7.5 300 mM NaCl 5% glycerol 0.5 mM TCEP) and the clarified 426 
lysate is purified by IMAC on a 5 mL HisTrap column (GE Healthcare). The IMAC elution 427 
was further purified by sizing on a 300 mL Superdex 200 prep grade column (GE Healthcare) 428 
packed in a 2.6 cm diameter housing. Included volume fractions were pooled and analysed by 429 
SDS-PAGE or LC-MS.  430 
Preliminary characterization of the TbCLK1 enzyme was carried out and the Km for ATP 431 
and MBP (Myelin basic protein, dephosphorylated, Sigma-Aldrich Catalogue no: 13-110, 432 
LOT: 3107375) substrate was found to be 9.3 ± 3.6 µM and 0.065 ± 0.02 mg ml-1, 433 
respectively. TbCLK1 and hCLK1 enzyme activity assays were performed in white 384 well, 434 
solid bottom, Small Volume™ plates (GREINER). The assay buffer contained 40 mM Tris 435 
(pH 7.5), 20 mM MgCl2, 0.1mg/ml BSA and 2 mM DTT. Each enzyme (TbCLK1 = 3 nM; 436 
hCLK1 = 50 nM) was first incubated with different compound serial dilutions or DMSO 437 
control during 10 min and then ATP (10 µM) and MBP substrate (0.1 mg ml-1) mixture was 438 
added to initiate the reaction. After 30 min reaction at room temperature, the ADP-Glo 439 
reagent and detection solution were added following the technical manual of ADP-GloTM 440 
kinase assay kit (Promega). The luminescence was measured on CLARIOstar BMG 441 
LABTECH microplate reader. In all the assays, staurosporine was used as positive control of 442 
inhibition.  Apparent IC50 values were plotted using GraphPad Prism software. The co-crystal 443 
 
 
structure of TbCLK1 with AB1 showed specific covalent interaction with cysteine 215. It 444 
may be possible that all AB series compounds with Michael acceptors have covalent 445 
inhibition of TbCLK1. Since biochemical SAR analysis for all AB series compounds was 446 
carried out beyond 10 min incubation with rCLK1, IC50s are represented as apparent IC50s. 447 
The AB1 compound showed time dependent inhibition of rCLK1 wherein IC50 plateaued 448 
around 20 min. 449 
For Western blotting parasites were washed with trypanosome dilution buffer (TDB) 450 
supplemented with 20 mM glucose. After centrifugation, the samples were resuspended in the 451 
RIPA buffer (New England Biolabs) supplemented with protease and phosphatase inhibitors 452 
obtained from Promega and Roche Life Science respectively. All samples were quantified by 453 
Bradford protein assay (Bio-Rad), 25 µg of protein was loaded, resolved in a 4-20% 454 
NuPAGE Bis-Tris gel (Invitrogen) in NuPAGE MOPS running buffer and transferred onto 455 
Hybond-C nitrocellulose membranes (GE Healthcare) at 350 mA for 2 hr or, for high 456 
molecular weight proteins, overnight at 4 oC. 457 
After transfer, membranes were washed once in 1x TBST (tris-buffered saline (TBS), 0.01% 458 
Tween-20 (Sigma Aldrich)) for 10 min then incubated for 1 hr in blocking solution (1x 459 
TBST, 5% BSA) or, if required, overnight at 4 oC. Next, the membrane was rinsed for 10 min 460 
in 1X TBST and placed in blocking buffer containing the required primary antisera for 1 hr at 461 
room temperature or overnight at 4 oC. The membrane was then washed 3 times with TBST 462 
and placed in blocking solution containing the appropriate fluorescent secondary antisera for 463 
1 hr. A list of antibodies is provided in Supplementary Methods. 464 
 465 
Determination of solubility, plasma protein binding, brain tissue binding and 466 
microsomal clearance. 467 
Solubility of AB0 and AB1 compounds were determined in a high-throughput 468 
thermodynamic solubility assay as described previously 34 . Plasma protein binding was 469 
determined for AB1 using mouse blood 34, whilst brain tissue binding was determined using 470 
rat brain tissues. Intrinsic metabolic clearance of AB0 and AB1 were determined in mouse, 471 
rat and human liver microsomes using the compound depletion approach and LC-MS/MS 472 
quantification 35. 473 
Crystallization, data collection, and structure determination.  474 
 
 
The TbCLK1/AB1 complex was formed by incubating TbCLK1 kinase domain (V117-475 
M465) with 1mM AB1 at room temperature for 2 hours. The excess AB1 was removed by 476 
dialysis overnight in buffer containing 25mM HEPES pH 7.5, 250mM NaCl, 0.5mM TCEP. 477 
The TbCLK1 kinase domain/AB1 complex was concentrated to 15 mg/ml for crystallization 478 
trials. Crystallization experiments were carried out at 4°C using the sitting-drop vapor 479 
diffusion setup. Crystals of the TbCLK1 kinase domain/AB1 complex grew out of a well 480 
containing 0.1M HEPES pH 7.5, 1.6M Ammonium Sulfate, 2% w/v Peg 1000. Crystals were 481 
cryo-protected in reservoir solution supplemented with 20% glycerol and flash-cooled in 482 
liquid nitrogen for data collection. Datasets were collected under cryogenic conditions 483 
(100K) at the Advanced Light Source (ALS) beamline 5.0.2. All data were processed using 484 
Xia236, employing XDS37 for data integration and AIMLESS38 for scaling. Molecular 485 
replacement were carried out using PHASER39 with coordinates from human CLK1 crystal 486 
structure (PDB ID 6FT8)40. Structure refinement was carried out in PHENIX41 alternated 487 
with manual fitting in Coot42. Data collection and structure refinement statistics are included 488 
in Extended data Table 1.  489 
Differential Scanning Fluorimetry (DSF) for CLK1 490 
Scanning fluorimetry (DSF) was performed on an Applied Biosystems Viia 7 RT PCR 491 
instrument, and data was analyzed using Protein Thermal Shift Software version 1.3 (Applied 492 
Biosystems/Thermo Fisher). Recombinant Trypanosoma brucei CLK1 wild-type or C215A 493 
protein was diluted to 5 µM in 25 mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, 494 
N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES) pH 7.5 300 mM NaCl 495 
5% glycerol and 1 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP). Compounds in 496 
DMSO or DMSO control was added to a final concentration of 2 mM DMSO and 50 uM 497 
compound. SYPRO Orange (Invitrogen/Thermo Fisher) was pre-diluted to 100x in the 498 
protein buffer and added to a final concentration of 10x. 70 ul of each condition was 499 
prepared. After 30 min of incubation, 3x 20 ul was aliquoted bubble-free into a 384 well PCR 500 
plate and covered with RT PCR compatible film, then centrifuged 10 min at 2000 rpm at 501 
room temperature, and read in the RT PCR instrument with the appropriate filters. The 502 
thermal shift program consisted of 3 minutes at 25 ˚C followed by a 25-95 ˚C ramp at 0.03 503 
˚C/second and 5 seconds at 95 ˚C. 504 
General Statistics. 505 
 
 
All statistical analysis was performed using GraphPad Prism 8 506 
(http://www.graphpad.com/scientific-software/prism/). The appropriate tests were conducted 507 
and are as detailed in the corresponding figure legends. 508 
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 621 
Figure legends 622 
Fig. 1 Pan kinetoplastid activity of amidobenzimidazole (AB) series.  623 
(a) Structure, anti-kinetoplastid parasite activity, cytotoxicity, tyrosine kinase inhibition 624 
and in vitro pharmacokinetics of AB0 and AB1. EC50, and CC50 represent half-625 
maximum growth inhibition concentration. hEGFR: human epidermal growth factor 626 
receptor enzyme. BTK: Bruton’s tyrosine kinase. IC50 represents half-maximum 627 
enzyme inhibition concentration. All the cellular and biochemical data presented were 628 
generated with minimum of n=2 or more independent biological replicates (each 629 
biological replicate had n=2 technical replicates). All physicochemical and in vitro 630 
pharmacokinetics experiments were carried out with at least n = 4 technical replicates 631 
(except for rat microsomal clearance for AB0, which had n =2 technical replicates).  632 
(b) Structure activity relationship of amidobenzimidazoles. Each dot represents one 633 
compound. Compounds with the Michael acceptor (orange circles) were more potent 634 
against T. b. brucei (Tbb pEC50) and had better lipophilic efficiency (clogP, calculated 635 
octanol-water partition coefficient) compared to non-Michael acceptor compounds 636 
(blue circles). AB0 (dark blue) and AB1 (dark orange). The Tbb pEC50 data are the 637 
negative logarithm of 50% growth inhibition of bloodstream form of T. b. brucei 638 
(minimum n = 2 biological replicates). The compounds on the left side of the two 639 
slanted dotted lines represent lipophilic ligand efficiency (LipE) of 3 and 4. The 640 
compounds above two horizontal dotted lines have EC50 of 1000 and 100 nM against 641 
bloodstream form T. b. brucei. 642 
(c) In vivo activity of AB1 in a haemolymphatic mouse model for human African 643 
trypanosomiasis (untreated control group, mice = 4; all the other experimental groups, 644 
mice = 6). Each group of mice were infected with T. b. brucei and 3 days post 645 
infection, mice were treated with varying concentration of AB1 for 4 days once daily 646 
and monitored for relapse in parasitemia over a period of 31 days. Cure plot (Kaplan–647 
Meier plot) showing percentage of animals cured over time are shown. Note the dose 648 
dependent activity of AB1, achieving complete cure at 50 mg kg-1 once daily dose (in 649 
violet).   650 
 651 
Fig. 2 Identification of CLK1 as the molecular target for the AB series.  652 
(a) Inducible overexpression (OE) of essential protein kinases (PKs) and target 653 
deconvolution approach for the AB series. Schematic representation of the 654 
experimental workflow: 6-myc OE plasmids, each containing a specific protein kinase 655 
tagged with six myc epitopes, were individually transfected into 2T1 bloodstream 656 
 
 
form T. b. brucei (VSG221 expressing, Tagged, clone 1). Viability of induced 657 
individual T. b. brucei OE lines after treatment was assessed by measuring the 658 
conversion of resazurin (Alamar blue) to resorufin. 659 
(b) AB1 half-maximal effective concentration (EC50) was analysed from twenty-nine 660 
essential individual protein kinase over-expression cell lines (dark grey circles). The 661 
graph represents EC50 fold change over the parental cell line (T. b. brucei 2T1 cell 662 
line, DMSO) (light grey shade box), where overexpression of CLK1 confers 663 
resistance to AB1. The grey bar represents the EC50 average of all cell lines over 664 
control.  Box error bars represent the library mean with 95% of confidence interval of 665 
two biological replicates of the library and CLK1 (n = 4 biological replicates). P-666 
value was calculated using two-tailed Student’s t-tests comparing CLK1 OE with 667 
parental cell line where *** p-value = 5 x 10-5. 668 
(c) CLK1 over-expression confers resistance to AB1-induced cell cycle arrest. CLK1 669 
over-expression was induced or not with tetracycline for 18 h, and cells then 670 
incubated for 6 h with 5x AB1 EC50 (dark grey bars); the 2T1 cell line was a parental 671 
control. Cell cycle distribution was determined by flow cytometry. Left: dotted line 672 
represents (basal) G2/M untreated average and *** represents a p-value =1.2 x 10-4 673 
(2T1 untreated vs AB1), p-value = 5.8 x 10-4 (CLK1 OE uninduced vs AB1), and not 674 
signficant  (ns) p-value = 0.02 (CLK1 OE induced vs AB1). P-value was calculated 675 
using two-tailed Student’s t-test. Error bars represent mean ± SEM of three biological 676 
replicates, Right: representative cell cycle profile histogram of cells stained with 677 
propidium iodide showing G2/M cell cycle accumulation (arrow).  678 
(d) Violin plot of average length (µm) of the nuclei from parasites treated (blue) or not 679 
(grey) with AB1 (n=160 2K1N parasites, *** p-value = 3.9 x 10-26). Dashed line 680 
represents the mean value, and dotted lines indicate both quartiles (25th & 75th). P-681 
value was calculated using unpaired two-tailed Student’s t-test. Right: Example of a 682 
cell stained with DAPI (cyan) from each condition, where N= nucleus, K= 683 
Kinetoplast.  684 
(e) Cell cycle analysis of synchronized T. b. brucei after treatment with AB1. Top: 685 
Kinetoplast/nucleus configuration of 2C and 4C synchronized parasites, treated or not 686 
with 5x EC50 AB1 was quantified by DAPI staining at the indicated points (n=200 687 
cells). K = kDNA, N = nucleus, D = duplicating kDNA.  Bottom: Schematic 688 
representation of T. brucei kinetoplast/nucleus configuration through the cell cycle. 689 
 690 
Fig. 3 Mechanism of CLK1 inhibition by AB1  691 
(a) Positive correlation between inhibition of recombinant T. brucei CLK1 enzyme 692 
(apparent pIC50) and growth inhibition (pEC50) of T. b. brucei bloodstream form 693 
parasites with AB series compounds (n=260; Pearson correlation coefficient (r) = 694 
0.68. Presence (orange) or absence (blue) of Michael acceptor pharmacophore is 695 
shown, highlighting AB1 (dark orange) and AB0 (dark blue). Black dash line 696 
represents equimolar potency and grey dash line represents 10-fold higher potency for 697 
CLK1 pIC50 compared to Tbb pEC50. 698 
(b) Lack of correlation between inhibition of recombinant human CLK1 (hCLK1) and 699 
recombinant T. brucei CLK1 enzyme (apparent pIC50) with AB compound series 700 
(n=228; Pearson correlation coefficient (r) = 0.03). Majority of compounds showed > 701 
10-fold selectivity against TbCLK1 compared to hCLK1. Presence (orange) or 702 
 
 
absence (blue) of Michael acceptor pharmacophore is shown, highlighting AB1 (dark 703 
orange) and AB0 (dark blue). Grey dash line represents equimolar potency and black 704 
dash line represents 10-fold higher potency for CLK1 pIC50 compared to hCLK1 705 
pIC50. 706 
(c) Crystal structure of the T. brucei CLK1 kinase domain (V117-M465) in a covalent 707 
thioether bond with AB1 at C215 (PDB: 6Q2A). The CLK1 kinase domain is shown 708 
in grey, with a blue αC helix, and the side chains of the DFG motif (DLG in CLK1) 709 
shown as sticks. Inhibitor AB1 is shown as ball and sticks with carbon coloured 710 
purple, oxygen coloured red and nitrogen coloured blue. A semi-transparent 711 
representation of AB1 van der Waals surfaces are shown in magenta. Inset depicts the 712 
detailed view of the interactions of AB1. Hydrogen bonds and salt bridge are shown 713 
as dotted blue line. MAP-like insertion is showed in orange. 714 
(d) Omit 2Fo-Fc map of AB1/C215 at 2.6Å resolution contoured at 2σ. Hydrogen bonds 715 
and salt bridge between the AB1 molecule and T. brucei bCLK1 are drawn as blue 716 
lines. Covalent bond indicated by yellow arrow. 717 
 718 
Fig. 4 CLK1 is the primary target for AB1 in bloodstream form trypanosomes 719 
(a) AB1 binding to CLK1, as probed via differential scanning fluorimetry (DSF). 720 
Thermal unfolding of CLK1 is monitored by SYPRO Orange. CLK1 WT (left) and 721 
CLK1 C215A (right) recombinant protein in the presence of AB0 (green), AB1 (red) 722 
or DMSO (blue) as a reference. Data from one representative experiment, out of three 723 
independent experiment with similar results, are shown. Note the shift in Tm (melting 724 
temperature of protein) for CLK1 in presence of AB1 compound. 725 
(b) Expression of T. brucei CLK1 C215A mutant is resistant to AB1. Dose-response 726 
curves of apparent AB1 and staurosporine IC50 of recombinant WT T. brucei CLK1 727 
and C215A mutant. Response to 3-fold serial dilutions of each compound were 728 
assessed as described in methods. Each data point represents the mean of two 729 
technical replicates. 730 
(c) Overexpression of CLK1 C215S mutant confers > 60-fold EC50 shift to AB1. CLK1 731 
C215S mutation (green) was overexpressed in the parental T. b. brucei 2T1 cell line 732 
and AB1 half-maximal effective concentration (EC50) was determined after 72 h and 733 
compared with T. b. brucei 2T1 WT parental cell line (blue). Data represent mean ± 734 
SEM of three independent biological experiments. Inset: Tetracycline inducible over-735 
expression of CLK1-myc was assessed for three clones by western blot, using an anti-736 
myc antibody. EF1α was used as the loading control. 737 
(d) Overexpression of CLK1 C215S mutant impairs the parasite growth effect of AB1 738 
treatment. Parasites overexpressing CLK1 C215S (green) and parental T. b. brucei 739 
2T1 cell line (blue) were treated with 5x (line) or 10x AB1 EC50 (dashed line) during 740 
48 h. Mean ± SEM (n=3) is shown. Data represent the mean of the percentage of cell 741 
growth relative to time=0 h (1.5 x 104 parasites ml-1). P values were calculated using a 742 
two-tailed Student’s t-test comparing with parental control where *** represent the P-743 
values of 24 h (p-value = 5.4 x 10-4), 48 h (p-value = 3.4 x 10-4), and 72 h (p-value = 744 
3.3 x 10-4) after treatment with 5x AB1 EC50, and 24 h (p-value = 9.9 x10
-7), 48 h (p-745 
value = 1.7 x 10-3), and 72 h (p-value = 1.6 x 10-3) for 10x AB1 EC50 treatment. 746 
 
 
(e) Percentage of survival of parasites exposed to 5-150x AB1 EC50 fold range. Parental 747 
T. b. brucei 2T1 control (blue) and CLK1 C215S mutant (green) (2 x 103 parasites ml-748 
1) were exposed for 72 h to 5, 15, 50, and 150-fold AB1 EC50. Survival was calculated 749 
by using CellTiter-Glo® luminescent cell viability assay. Data represent the mean ± 750 
SEM of percentage of survival. (C215S mutant n=3, Parental 2T1 n=4). 751 
Fig. 5 CLK1 inhibition impairs inner kinetochore dynamics. 752 
(a) Localization of kinetochore protein KKT2 after CLK1 inhibition by AB1. Parasites 753 
were incubated or not for 24 h with 2x EC50 (upper panel) or 6 h with 5 x EC50 AB1 754 
(lower panel). Representative fluorescence micrographs, showing bloodstream form 755 
parasites endogenously expressing N-terminal mNeonGreen (mNG) tagged KKT2. 756 
Cells in metaphase and anaphase are shown. Cells were counterstained with DAPI to 757 
visualize DNA (cyan). The right panel shows the Nomarsky (DIC) corresponding 758 
images. Upper right panel shows cell cycle progression after treatment with 2x EC50 759 
AB1 for 72 h. Data are representative from one of three independent biological 760 
replicates with similar results. 761 
(b) Localization of KKT2 after CLK1 depletion by RNAi. Representative fluorescence 762 
micrographs, showing 24 h induction of CLK1 RNAi in bloodstream form parasites 763 
endogenously expressing N-terminal mNeonGreen (mNG) labelled KKT2, compared 764 
with not induced control cells in metaphase and anaphase are shown. Cells were 765 
counterstained with DAPI to visualize DNA (cyan). The right panel shows the 766 
Nomarsky (DIC) corresponding images. Data are representative from one of three 767 
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